文献速递临床免疫

无标记免疫分析法用于单克隆抗体药物及抗药抗体检测的新方案

Development of Label-Free Immunoassays as Novel Solutions for the Measurement of Monoclonal Antibody Drugs and Antidrug Antibodies.
PubMed 文献 · Clin Chem · 2020-01-01

基于薄膜干涉测量技术开发了开放获取的无标记免疫分析法,用于定量阿达木单抗和英夫利西单抗及检测其抗药抗体。两种药物分析测量范围均为2–100 μg/mL,抗药抗体检测范围分别为5–100 μg/mL和10–100 μg/mL。与报告基因法比较,阿达木单抗和英夫利西单抗定量相关系数分别为0.972和0.940,抗药抗体检测一致率分别为90%和76%。

要点

  • 无标记免疫分析法可在数分钟内完成单抗药物定量。
  • 阿达木单抗和英夫利西单抗分析测量范围均为2–100 μg/mL。
  • 与报告基因法比较,药物定量相关性高,抗药抗体检测一致率分别为90%和76%。

核心结论

  • 基于薄膜干涉测量技术的无标记免疫分析法适用于阿达木单抗和英夫利西单抗的治疗药物监测。

研究设计与样本

  • 基于薄膜干涉测量技术开发开放获取的无标记免疫分析法,用于定量阿达木单抗和英夫利西单抗及检测其抗药抗体,并进行了验证。

主要发现

  • 阿达木单抗和英夫利西单抗的分析测量范围均为2–100 μg/mL。
  • 阿达木单抗抗药抗体的分析测量范围为5–100 μg/mL,英夫利西单抗抗药抗体的分析测量范围为10–100 μg/mL。
  • 与报告基因法比较,阿达木单抗定量的相关系数为0.972,英夫利西单抗定量的相关系数为0.940。
  • 阿达木单抗抗药抗体检测的一致率为90%,英夫利西单抗抗药抗体检测的一致率为76%。

关键数值与推荐

  • 阿达木单抗和英夫利西单抗的分析测量范围均为2–100 μg/mL。
  • 阿达木单抗抗药抗体的分析测量范围为5–100 μg/mL。
  • 英夫利西单抗抗药抗体的分析测量范围为10–100 μg/mL。
  • 与报告基因法比较,阿达木单抗定量相关系数为0.972,英夫利西单抗定量相关系数为0.940。
  • 阿达木单抗抗药抗体检测一致率为90%,英夫利西单抗抗药抗体检测一致率为76%。

临床怎么用

  • 该无标记免疫分析法可用于阿达木单抗和英夫利西单抗的治疗药物监测。
  • 开放获取的无标记免疫分析法在临床诊断中具有较大潜力。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Immunoassays based on label-free technologies (label-free immunoassay [LFIA]) offer an innovative approach to clinical diagnostics and demonstrate great promise for therapeutic drug monitoring (TDM) of monoclonal antibody (mAb) drugs. An LFIA measures immunocomplex formation in real time and allows for quantification on initial binding rate, which facilitates fast measurement within a few minutes. METHODS: Based on thin-film interferometry (TFI) technology, open-access LFIAs were developed for the quantification of the mAb drugs adalimumab (ADL) and infliximab (IFX) and for the detection of the antidrug antibodies (ADAs) to the mAb drugs (ADL-ADAs and IFX-ADAs). RESULTS: The LFIAs for active mAb drugs (ADL and IFX) and for ADAs (ADL-ADAs and IFX-ADAs) were validated. The analytical measurement range (AMR) for both ADL and IFX was from 2 to 100 μg/mL. The AMR for ADL-ADAs was from 5 to 100 μg/mL and for IFX-ADAs was 10 to 100 μg/mL. In the comparison of LFIAs and reporter gene assays, the correlation coefficient was 0.972 for the quantification of ADL and 0.940 for the quantification of IFX. The concordance rate was 90% for the detection of ADL-ADAs and 76% for the detection of IFX-ADAs. CONCLUSIONS: The LFIAs for active mAb drugs and ADAs were appropriate for the TDM of ADL and IFX. The TFI technology has unique advantages compared with other technologies used for the measurement of mAb drugs. Label-free technologies, especially those allowing for open-access LFIAs, have great potential for clinical diagnostics.

来源:Clin Chem,查看原文。版权归原作者所有。

引用

  1. Luo YR, Chakraborty I, Lazar-Molnar E, et al. Development of Label-Free Immunoassays as Novel Solutions for the Measurement of Monoclonal Antibody Drugs and Antidrug Antibodies. Clin Chem. 2020. PMID: 32918468. doi:10.1093/clinchem/hvaa179

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。